Nan Jian Qiu

Dr. Nan Jian Qiu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
JZJi Zhu
Ji Zhu
JGJianan Guo
Jianan Guo
ZLZhijun Liu
Zhijun Liu
JLJing Liu
Jing Liu
AYAini Yuan
Aini Yuan
YLYifei Le
Yifei Le

22 March 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JGJianan Guo
Jianan Guo
YLYifei Le
Yifei Le
AYAini Yuan
Aini Yuan
JLJing Liu
Jing Liu
HCHang Chen
Hang Chen
DLDezhao Lu
Dezhao Lu


28 September 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YLYifei Le
Yifei Le
JGJianan Guo
Jianan Guo
ZLZhijun Liu
Zhijun Liu
JLJing Liu
Jing Liu
YLYing Liu
Ying Liu
DLDezhao Lu
Dezhao Lu

19 December 2023 in Molecules
Verified
Journal Article
Open access
PDF file
YLYuchen Liu
Yuchen Liu
GWGang Wei
Gang Wei
ZLZhi-Qiang Liao
Zhi-Qiang Liao
FWFang-Xin Wang
Fang-Xin Wang
CZChunxiao Zong
Chunxiao Zong
CWCAI YI WANG
CAI YI WANG
Peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase 1 (CPT1) are important targets of lipid metabolism regulation for nonalcoholic fatty liver disease (NAFLD) therapy. In the present study, a set of novel indole ethylamine derivatives (4, 5, 8, 9) were designed and synthesized. The target product (compound 9) can effectively activate PPARα and CPT1a. Consistently, in vitro assays demonstrated its impact on the lipid accumulation of oleic acid (OA)-induced AML12 cells. Compared with AML12 cells treated only with OA, supplementation with 5, 10, and 20 μM of compound 9 reduced the levels of intracellular triglyceride (by 28.07%, 37.55%, and 51.33%) with greater inhibitory activity relative to the commercial PPARα agonist fenofibrate. Moreover, the compound 9 supplementations upregulated the expression of hormone-sensitive triglyceride lipase (HSL) and adipose triglyceride lipase (ATGL) and upregulated the phosphorylation of acetyl-CoA carboxylase (ACC) related to fatty acid oxidation and lipogenesis. This dual-target compound with lipid metabolism regulatory efficacy may represent a promising type of drug lead for NAFLD therapy.

12 January 2026 in Phytomedicine
Verified
Journal Article
Closed access
JDJing Ding
Jing Ding
FXFangying Xu
Fangying Xu
DCDi Chen
Di Chen
JXJiale Xi
Jiale Xi
FGFengrui Gao
Fengrui Gao
GHGuonong He
Guonong He